open access

Vol 59, No 2 (2021)
Original paper
Submitted: 2020-11-30
Accepted: 2021-04-29
Published online: 2021-05-18
Get Citation

Decreased immunoreactivity of von Willebrand factor may reflect persistent nature of the endothelial dysfunction in non-ischemic heart failure

Edyta Reichman-Warmusz1, Marlena Brzozowa-Zasada1, Celina Wojciechowska2, Damian Dudek13, Oliwia Warmusz1, Romuald Wojnicz1
DOI: 10.5603/FHC.a2021.0012
·
Pubmed: 34003485
·
Folia Histochem Cytobiol 2021;59(2):108-113.
Affiliations
  1. Department of Histology and Cell Pathology, Medical University of Silesia in Katowice, School of Medicine with the Division of Dentistry, Zabrze, Poland
  2. Second Department of Cardiology, Medical University of Silesia, School of Medicine with the Division of Dentistry, Poland
  3. Ambulatory Oral Surgery and Implantology, Torun, Poland

open access

Vol 59, No 2 (2021)
ORIGINAL PAPERS
Submitted: 2020-11-30
Accepted: 2021-04-29
Published online: 2021-05-18

Abstract

Introduction. Endothelial dysfunction is a critical part of heart failure (HF) pathophysiology. It is not clear, however, whether it is present at the similar level in the early and late HF stages.

Material and methods. von Willebrand factor (vWF) and its mRNA levels in biopsies of non-ischemic patients with HF secondary to dilated cardiomyopathy were studied. Consecutive patients with HF were divided into two groups: group A with disease duration ≤ 12 months (n = 59) and group B with disease duration > 12 months (n = 68). The immunoreactivity of the vWF was compared with autopsy sections of 19 control cases. Tissue vWF gene expression was analyzed at the mRNA level by RT-PCR.

Results. In the group A, there was lower vWF immunoreactivity in the coronary microvessels compared to the group B [1.5 (1.0–2.0) vs. 2.0 (1.5–2.4), P = 0.001]. In the control group, only weak vWF expression was observed. Protein expression was not accompanied by vWF mRNA whose levels were significantly higher in the Group A as compared to the Group B [14671 (4932-51561) vs. 3643 (185.3–9030.8), P = 0.005]. Protein vWF expression was inversely associated with its mRNA levels (r = –0.34, P = 0.04).

Conclusions. High myocardial protein expression of vWF in patients with long-lasting HF symptoms may
highlight the persistent nature of endothelial dysfunction in such a cohort of patients.

Abstract

Introduction. Endothelial dysfunction is a critical part of heart failure (HF) pathophysiology. It is not clear, however, whether it is present at the similar level in the early and late HF stages.

Material and methods. von Willebrand factor (vWF) and its mRNA levels in biopsies of non-ischemic patients with HF secondary to dilated cardiomyopathy were studied. Consecutive patients with HF were divided into two groups: group A with disease duration ≤ 12 months (n = 59) and group B with disease duration > 12 months (n = 68). The immunoreactivity of the vWF was compared with autopsy sections of 19 control cases. Tissue vWF gene expression was analyzed at the mRNA level by RT-PCR.

Results. In the group A, there was lower vWF immunoreactivity in the coronary microvessels compared to the group B [1.5 (1.0–2.0) vs. 2.0 (1.5–2.4), P = 0.001]. In the control group, only weak vWF expression was observed. Protein expression was not accompanied by vWF mRNA whose levels were significantly higher in the Group A as compared to the Group B [14671 (4932-51561) vs. 3643 (185.3–9030.8), P = 0.005]. Protein vWF expression was inversely associated with its mRNA levels (r = –0.34, P = 0.04).

Conclusions. High myocardial protein expression of vWF in patients with long-lasting HF symptoms may
highlight the persistent nature of endothelial dysfunction in such a cohort of patients.

Get Citation

Keywords

heart failure; dilated cardiomyopathy; endomyocardial biopsy; endothelial dysfunction; von Willebrand factor; qPCR; IHC

About this article
Title

Decreased immunoreactivity of von Willebrand factor may reflect persistent nature of the endothelial dysfunction in non-ischemic heart failure

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 59, No 2 (2021)

Article type

Original paper

Pages

108-113

Published online

2021-05-18

DOI

10.5603/FHC.a2021.0012

Pubmed

34003485

Bibliographic record

Folia Histochem Cytobiol 2021;59(2):108-113.

Keywords

heart failure
dilated cardiomyopathy
endomyocardial biopsy
endothelial dysfunction
von Willebrand factor
qPCR
IHC

Authors

Edyta Reichman-Warmusz
Marlena Brzozowa-Zasada
Celina Wojciechowska
Damian Dudek
Oliwia Warmusz
Romuald Wojnicz

References (22)
  1. Rosamond W, Flegal K, Furie K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117(4): e25–146.
  2. Mosterd A, Hoes AW, Mosterd A, et al. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146. .
  3. Inoue T, Sakai Y, Morooka S, et al. Coronary flow reserve in patients with dilated cardiomyopathy. Am Heart J. 1993; 125(1): 93–98.
  4. Salgado DR, Favory R, Rocco JR, et al. Microcirculatory effects of angiotensin II inhibitors in patients with severe heart failure. Clin Hemorheol Microcirc. 2013; 54(1): 87–98.
  5. van Hinsbergh VWM. Endothelium--role in regulation of coagulation and inflammation. Semin Immunopathol. 2012; 34(1): 93–106.
  6. Zuchi C, Tritto I, Carluccio E, et al. Role of endothelial dysfunction in heart failure. Heart Fail Rev. 2020; 25(1): 21–30.
  7. Chen JW, Ting CT, Chen YH, et al. Differential coronary microvascular function in patients with left ventricular dysfunction of unknown cause — implication for possible mechanism of myocardial ischemia in early stage of cardiomyopathy. Int J Cardiol. 1999; 69(3): 251–261.
  8. Heuvel Av, Veldhuisen Dv, Wall Ev, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000; 35(1): 19–28.
  9. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002; 105(2): 186–193.
  10. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J. 2005; 26(1): 65–69.
  11. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005; 111(3): 310–314.
  12. Lerman A, Zeiher A. Endothelial Function. Circulation. 2005; 111(3): 363–368.
  13. Ruggeri Z. Structure and Function of von Willebrand Factor. Thromb Haemost. 2017; 82(08): 576–584.
  14. Gombos T, Makó V, Cervenak L, et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost. 2009; 102(3): 573–580.
  15. Nowroozpoor A, Gutterman D, Safdar B. Is microvascular dysfunction a systemic disorder with common biomarkers found in the heart, brain, and kidneys? - A scoping review. Microvasc Res. 2021; 134: 104123.
  16. Galatius S, Wroblewski H, Sørensen V, et al. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: Different stimuli for release before and after heart transplantation? Am Heart J. 1999; 137(3): 549–554.
  17. El-Mansi S, Nightingale TD. Emerging mechanisms to modulate VWF release from endothelial cells. Int J Biochem Cell Biol. 2021; 131: 105900.
  18. Kleber ME, Koller L, Goliasch G, et al. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail. 2015; 8(1): 25–32.
  19. Zannad F, Stough WG, Regnault V, et al. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol. 2013; 167(5): 1772–1782.
  20. Lip GYH, Pearce LA, Chin BSP, et al. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart. 2005; 91(6): 759–763.
  21. Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001; 103(13): 1746–1751.
  22. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001; 37(5): 1436–1442.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl